UK markets closed

Cyclacel Pharmaceuticals, Inc. (CYCC)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
2.2900-0.0500 (-2.14%)
At close: 04:00PM EDT
2.3300 +0.04 (+1.75%)
After hours: 06:22PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 3.42M
Enterprise value 83.03k
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)4.74
Price/book (mrq)5.64
Enterprise value/revenue 0.20
Enterprise value/EBITDA 0.40

Trading information

Stock price history

Beta (5Y monthly) 0.55
52-week change 3-76.00%
S&P500 52-week change 326.36%
52-week high 313.2000
52-week low 31.3000
50-day moving average 32.1504
200-day moving average 34.2828

Share statistics

Avg vol (3-month) 3815.25k
Avg vol (10-day) 3255.6k
Shares outstanding 51.46M
Implied shares outstanding 61.46M
Float 81.16M
% held by insiders 16.41%
% held by institutions 115.16%
Shares short (30 Apr 2024) 4351.07k
Short ratio (30 Apr 2024) 40.28
Short % of float (30 Apr 2024) 428.38%
Short % of shares outstanding (30 Apr 2024) 426.63%
Shares short (prior month 28 Mar 2024) 424.34k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 315 Apr 2020
Ex-dividend date 4N/A
Last split factor 21:15
Last split date 318 Dec 2023

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-17,290.32%

Management effectiveness

Return on assets (ttm)-86.33%
Return on equity (ttm)-272.63%

Income statement

Revenue (ttm)420k
Revenue per share (ttm)0.49
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -25.42M
Net income avi to common (ttm)-22.76M
Diluted EPS (ttm)-26.7500
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)3.38M
Total cash per share (mrq)2.56
Total debt (mrq)37k
Total debt/equity (mrq)6.10%
Current ratio (mrq)0.91
Book value per share (mrq)0.57

Cash flow statement

Operating cash flow (ttm)-16.11M
Levered free cash flow (ttm)-11.76M